Context Announces Presentation of New Antiprogestin at the 2019 AACR Annual Meeting

CTX-30916 identified as a potent Progesterone Receptor (PR) antagonist.

Highlights Company’s Leadership in Selective Progesterone Receptor Antagonism

Philadelphia, PA, February 27, 2019 – Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on CTX-30916, a new PR antagonist, will be featured at the upcoming AACR Annual Meeting taking place in Atlanta, Georgia. The data will be presented during the Receptors and Growth Factors session on April 1, 2019 from 1:00 PM - 5:00 PM.

At the conference Dr. Deepak Lala, Ph.D., Chief Technology Officer for Context Therapeutics and Dr. Tasir Haque Ph.D., Head of Chemistry for Context Therapeutics will present preclinical data highlighting the biochemical and cellular activity of CTX-30916 including its mechanism of action in inhibiting breast cancer cell proliferation. CTX-30916 is a next generation PR antagonist with potential for the treatment of breast, uterine, and ovarian cancers.

The poster details are as follows:

Poster Title:  Identification of CTX-30916 as a new antagonist of progesterone receptor signaling pathways

Session Category:   Molecular and Cellular Biology / Genetics

Session Title:  Receptors and Growth Factors

Session Date and Time:   Monday Apr 1, 2019 1:00 PM - 5:00 PM

Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 38

Poster Board Number:  4

Abstract Number: 2625

For more information on AACR 2019, please visit

About Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, endometrial, and ovarian cancers. In addition, Context is advancing CTX-30916, a preclinical progesterone receptor antagonist. For more information on Context, visit


Context Contact

Tasir Haque, PhD
Head of Chemistry

Deepak Lala, PhD
Chief Technology Officer


Investor Contact

Solebury Trout
Michael Levitan

News ReleasesMartin Lehr